SUBSCRIBE
SUBSCRIBE

Johnson & Johnson Family of Companies

NEWS
Biotech Bay
Will Flawed All-Metal Hip Replacements Cost Johnson & Johnson and Zimmer $5 Billion?
December 28, 2011
 · 
1 min read
Pharm Country
Johnson & Johnson Neuroscience Head Urges Pooling of Brain R&D
October 18, 2011
 · 
2 min read
Job Trends
A Grieving Johnson & Johnson Employee And Cubicle Photos
September 6, 2011
 · 
1 min read
Biotech Bay
Drug Companies Lose Protections on Facebook; Johnson & Johnson, AstraZeneca PLC Decide to Close Pages
August 15, 2011
 · 
1 min read
Pharm Country
Merck & Co., Inc. and Johnson & Johnson Sit on Piles of Cash
August 9, 2011
 · 
1 min read
Pharm Country
Johnson & Johnson’s Push into Emerging Markets Will Require Retooling Sophisticated, Expensive Medical Devices
June 22, 2011
 · 
1 min read
Pharm Country
Johnson & Johnson’s Prostate Cancer Drug Extends Life While Spurring $5 Billion Market
June 2, 2011
 · 
1 min read
Policy
Metal Hip Replacements: Toxic Effects? - FDA Asks
May 16, 2011
 · 
1 min read
Pharm Country
Drugmakers Including Johnson & Johnson and Procter & Gamble Eliminate Infant Drops of Key Medicine
May 5, 2011
 · 
1 min read
Load More
AWARDS
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
JOBS
IN THE PRESS
Press Releases
Johnson & Johnson completes acquisition of Halda Therapeutics and its novel platform to revolutionize cancer treatment and enable next-generation oral therapies
December 29, 2025
 · 
5 min read
Press Releases
European Commission approves TREMFYA® (guselkumab) for the treatment of children with plaque psoriasis, marking the first paediatric indication for an IL-23 inhibitor
December 22, 2025
 · 
14 min read
Press Releases
Johnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma
December 19, 2025
 · 
6 min read
Press Releases
U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib)
December 18, 2025
 · 
33 min read
Press Releases
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results - December 15, 2025
December 16, 2025
 · 
1 min read
Press Releases
Link Cell Therapies Launches with Vision of Advancing CAR-T Therapies in Solid and Liquid Tumors
December 16, 2025
 · 
4 min read
Press Releases
U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*
December 15, 2025
 · 
20 min read
Press Releases
Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI®▼ (teclistamab) plus DARZALEX® (daratumumab) subcutaneous formulation as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
December 10, 2025
 · 
18 min read
Press Releases
Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
December 10, 2025
 · 
28 min read
Press Releases
Johnson & Johnson to Participate in the 44th Annual J.P. Morgan Healthcare Conference
December 9, 2025
 · 
1 min read
Load More